Phase I/II Evaluation of the Immune Checkpoint Inhibitor, Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Decitabine (Primary) ; Pembrolizumab (Primary) ; Tetrahydrouridine (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 19 Dec 2017
- 25 Nov 2017 Planned initiation date changed from 27 Nov 2017 to 1 Dec 2017.
- 24 Nov 2017 Planned initiation date changed from 2 Nov 2017 to 30 Nov 2017.